Stati Uniti - inglese - NLM (National Library of Medicine)

alvogen, inc - gadopentetate dimeglumine (unii: rh248g8v27) (gadopentetate - unii:v7ok6j19hq) - gadopentetate dimeglumine 469.01 mg in 1 ml - gadopentetate dimeglumine injection is indicated for use with magnetic resonance imaging (mri) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. gadopentetate dimeglumine injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors. gadopentetate dimeglumine is indicated for use with mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the head and neck. gadopentetate dimeglumine injection is indicated for use in mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart). gadopentetate dimeglumine is contraindicated in patients with:

Stati Uniti - inglese - NLM (National Library of Medicine)

alvogen, inc - gadopentetate dimeglumine (unii: rh248g8v27) (gadopentetate - unii:v7ok6j19hq) - gadopentetate dimeglumine injection is indicated for use with magnetic resonance imaging (mri) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. gadopentetate dimeglumine injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors. gadopentetate dimeglumine is indicated for use with mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the head and neck. gadopentetate dimeglumine injection is indicated for use in mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart). gadopentetate dimeglumine injection is contraindicated in patients with:

Stati Uniti - inglese - NLM (National Library of Medicine)

hameln pharmaceuticals - pentetate zinc trisodium (unii: nxu65ic8pg) (pentetic acid - unii:7a314hqm0i) - injection, solution, concentrate - 200 mg in 1 ml - zn-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none known.

Stati Uniti - inglese - NLM (National Library of Medicine)

hameln pharmaceuticals - pentetate calcium trisodium (unii: g79yn26h5b) (pentetic acid - unii:7a314hqm0i) - injection, solution, concentrate - 200 mg in 1 ml - ca-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none known.

Stati Uniti - inglese - NLM (National Library of Medicine)

hameln pharma gmbh - pentetate calcium trisodium (unii: g79yn26h5b) (pentetic acid - unii:7a314hqm0i) - pentetate calcium trisodium 1000 mg in 5 ml - ca-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none. pregnancy category c risk summary there are no adequate and well-controlled studies of ca-dtpa use in pregnant women. ca-dtpa chelation therapy causes depletion of body stores of zinc, a trace metal essential for fetal development [see warnings and precautions (5.2)] . the consequences of zinc depletion and results of animal studies suggest a teratogenic risk in humans. ca-dtpa was teratogenic and embryotoxic in mice at daily doses 2 to 8 times the recommended daily human dose, based on body surface area (bsa), with a dose-dependent increase in the frequency of gross malformations. ca-dtpa was teratogenic in dogs at approximately half the recommended daily human dose based on bsa, as described below. there are no animal or human data evaluating the teratogenic effect of a single dose of ca-dtpa. ca-dtpa should be used during pregnancy